Nepal approves conditional emergency use of Russia’s Sputnik V COVID-19 vaccine

Picture- Agency

As the persistent drumbeat of positive tests and reported deaths in Nepal due to COVID-19, Nepal’s national drug regulatory authority gave conditional approval on Tuesday for the emergency use of the Russian Sputnik V COVID-19 vaccine.

Sputnik V is a viral vector vaccine for Covid-19 developed by Gamaleya Research Institute of Epidemiology and Microbiology of Russia.

According reports, Russian scientists have found the Sputnik V vaccine 97.6% effective against COVID-19 in a “real-world” assessment based on data from 3.8 million people, Moscow’s Gamaleya Institute and the Russian Direct Investment Fund said on Monday.

The new effectiveness rate is higher than the 91.6% rate outlined in results from a large-scale trial of Sputnik V that was published in The Lancet medical journal earlier this year, and compares favourably with data on the effectiveness of other COVID-19 vaccines.

The new data was based on 3.8 million Russians who received both a first shot and a booster shot as part of the national roll-out of Sputnik V.

With Sputnik V, the number of vaccines granted emergency use has climbed to four. Lomus Pharmaceuticals had applied for its emergency use. The vaccines should be stored in 2 to 8 degree Celsius and it is supported by Nepal’s infrastructures.


Please enter your comment!
Please enter your name here